Monopar Therapeutics Inc
MNPR
NASDAQ
Biotechnology
$113.04
USD
+2.63 (+2.38%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $737.90M
Volume 165.7K
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-17.84M
TTM
-3.1%
YoY
Operating Cash Flow
$-12.18M
TTM
-24.1%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 1.5 | 1.5 | 2.2 | 1.7 | 1.9 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 3.2 | 4.1 | 6.2 | 5.2 | 6.6 |
Operating Income | -3.2 | -4.1 | -6.2 | -5.2 | -6.6 |
EBITDA | -3.2 | -4.1 | -6.2 | -5.2 | -6.6 |
Other Income / Expense | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Other Income / Expense | 0.8 | 0.7 | 1.0 | 1.3 | 1.3 |
Income Before Income Taxes | -2.5 | -3.4 | -5.2 | -3.9 | -5.3 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -2.5 | -3.4 | -5.2 | -3.9 | -5.3 |
Consolidated Net Income / Loss | -2.5 | -3.4 | -5.2 | -3.9 | -5.3 |
Net Income Attributable to Common Shareholders | -2.5 | -3.4 | -5.2 | -3.9 | -5.3 |
Basic EPS | -$0.35 | -$0.48 | -$0.61 | -$0.46 | -$0.62 |
Diluted EPS | -$0.35 | -$0.48 | -$0.61 | -$0.46 | -$0.62 |
Basic Shares Outstanding | 7.0M | 7.1M | 8.5M | 8.5M | 8.5M |
Diluted Shares Outstanding | 7.0M | 7.1M | 8.5M | 8.5M | 8.5M |